Jenna Cohen
About Jenna Cohen
Jenna Cohen is Chief Corporate Affairs Officer at Bicara Therapeutics, appointed as part of the expanded management team announced on November 10, 2025; she also serves as the investor contact for the company’s IR communications . She brings ~15 years of experience across communications, investor relations, market access, and policy, most recently as VP, Investor Relations and Global Business Communications at Blueprint Medicines; she began her career in market access/policy roles at Gilead Sciences and Avalere Health, and holds a B.S. in Biological Sciences with a minor in Communications from Cornell University . Bicara entered Q4 2025 with $407.6M cash and investments and expects runway into 1H 2029; the company is pre-revenue, investing heavily in pivotal and expansion trials, with Q3 2025 net loss of $36.3M .
Company operating snapshot relevant to Cohen’s IR mandate:
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Research & Development Expenses ($USD Millions) | $15.9 | $33.0 |
| General & Administrative Expenses ($USD Millions) | $4.8 | $7.7 |
| Net Loss ($USD Millions) | $17.5 | $36.3 |
| Metric | Dec 31, 2024 | Sep 30, 2025 |
|---|---|---|
| Cash, Cash Equivalents & Investments ($USD Millions) | $489.7 | $407.6 |
| Runway Guidance | — | Into 1H 2029 |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Blueprint Medicines (acquired by Sanofi July 2025) | VP, Investor Relations & Global Business Communications | — | Led narrative and IR strategy through bear market, global AYVAKIT launch, portfolio shifts, and sale to Sanofi . |
| Gilead Sciences | Commercial Market Access, Government Affairs & Policy (various roles) | — | Advanced market access and policy initiatives supporting portfolio execution . |
| Avalere Health | Policy roles | — | Health policy analysis and strategy for life sciences stakeholders . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Fierce Biotech Week | Speaker/Panelist, Reimagining Trust and Credibility in Pharma & Biotech Communications | 2025 | Thought leadership on credibility and IR/communications best practices . |
Fixed Compensation
- Not disclosed. Bicara, as an “emerging growth company,” provides scaled executive compensation disclosure and did not include Jenna Cohen in the 2024 named executive officer tables .
Performance Compensation
- Not disclosed for Cohen. Bicara’s EGC status exempts it from pay-versus-performance disclosures and advisory votes on executive compensation at this stage .
Equity Ownership & Alignment
- Beneficial ownership tables as of April 14, 2025 list greater-than-5% holders and named executive officers; Jenna Cohen is not included among principal stockholders or NEOs at that date .
- Policy environment: Bicara prohibits derivative transactions and pledging of company stock by insiders; maintains a Rule 10b5‑1 plan policy enabling pre-arranged trading plans, and an insider trading policy filed with its 10-K .
- Clawback: The company maintains an SEC/Nasdaq-compliant clawback policy requiring recovery of incentive-based compensation after material restatements within a 3-year lookback .
Employment Terms
- Appointment: Corporate highlight announced Nov 10, 2025 expanding management team with Jenna Cohen as Chief Corporate Affairs Officer .
- Item 5.02 filing: No 8‑K Item 5.02 appointment/compensation terms were found in 2024–2025 for Cohen; employment agreement, severance, and change-in-control terms for her role are not disclosed in available filings [functions ListDocuments returned no 8-K 5.02 for BCAX].
- Benefits environment: Company offers 401(k) with match and profit sharing for eligible employees; executive-level specifics for Cohen not disclosed .
Investment Implications
- Near-term IR and communications leverage: Cohen’s addition signals a more proactive capital markets posture as Bicara executes pivotal FORTIFI-HN01 and Phase 1b expansions; expect enhanced guidance cadence, investor targeting, and event presence, potentially reducing information asymmetry and improving liquidity .
- Insider selling pressure and alignment: No Form 4 filings referencing Cohen were identified; company policies prohibit pledging and derivative trading, and allow 10b5‑1 plans—reducing misalignment risks though future grants/filings could introduce vesting-related selling events; monitor subsequent 8‑Ks and Form 4s for award details and trading plans .
- Compensation alignment visibility: EGC scaled disclosure limits transparency on Cohen’s pay mix, performance metrics, severance, and change-of-control economics; analysts should watch for next proxy cycle or any 8‑K 5.02 disclosures to assess pay-for-performance alignment .
- Company fundamentals context: With $407.6M cash/investments and runway into 1H 2029, Bicara’s continued spend on R&D and growing G&A supports clinical execution; improved IR under Cohen may tighten the narrative during pivotal trial milestones, but dilution or secondary offerings remain a sector risk given pre-revenue status .